LONDON, June 2 (Reuters) - GlaxoSmithKline said on
Thursday it now expects to file its new three-in-one inhaled
lung drug for U.S. approval by the end of 2016, rather than the
first half of 2018 as previously expected, in a boost for its
pivotal respiratory business.
Read more
No comments:
Post a Comment